Drug Approval | July 05, 2024
Briefs: Alembic Pharmaceuticals and Relonchem
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
The inspection was conducted at its Goa, Vema manufacturing facility
Plans to double its manufacturing footprint to bolster the growth
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
Subscribe To Our Newsletter & Stay Updated
